GUANGJI PHARMA.(SZ:000952)2025-05-20 10:32Group 1: Company Performance and Financials - The company's revenue from exports accounted for 39.15% of total revenue in 2024, with the U.S. market contributing approximately 35% of export sales [2] - As of March 2025, the company's revenue indicators were slightly below schedule, with a net profit indicator showing a loss of 28.20% year-on-year [3] Group 2: Product Development and Research - The company is actively advancing its human milk oligosaccharides project in collaboration with Jiangnan University, aiming for product approval and market launch [2] - The company has obtained EU registration for riboflavin and riboflavin phosphate products, which are now authorized for sale in the EU market [3] Group 3: Strategic Initiatives and Future Plans - The company is committed to a "second entrepreneurship" strategy focused on high-quality development, enhancing product competitiveness, and optimizing resource allocation [3] - In response to national "dual carbon" goals, the company is integrating sustainable development into its operations and has been recognized as a national-level green factory [3] Group 4: Innovation and Technology - Currently, the company does not utilize AI in drug research but is monitoring developments in this area for future applications [3] - The company collaborates with universities and research institutions to develop new products and promote the industrialization of synthetic biology projects [2]